Pharma

With two weeks un­til Pres­i­dent-elect Don­ald Trump’s ad­min­is­tra­tion takes over, the FDA on Mon­day re­leased dozens of new draft and fi­nal guid­ance doc­u­ments cov­er­ing every­thing

San Diego-based Velia Ther­a­peu­tics, which was work­ing on so-called mi­cro­pro­teins, is in the process of wind­ing down about two years af­ter a $55 mil­lion Se­ries

WuXi Bi­o­log­ics’ sub­sidiary WuXi Vac­cines is di­vest­ing a man­u­fac­tur­ing fa­cil­i­ty in Dun­dalk, Ire­land, to Mer­ck for $500 mil­lion, rough­ly a week af­ter WuXi AppTec al­so

Plus, news about Gen­er­al Prox­im­i­ty and PBS Biotech: I-Mab paus­es CD73 de­vel­op­ment: The com­pa­ny is not mov­ing for­ward with a pro­gram … Sign up to

The first bio­phar­ma ven­ture fund to close in 2025 comes from in­dus­try vet­er­ans Joe Jimenez and Mark Fish­man, two for­mer No­var­tis lead­ers. Jimenez ex­clu­sive­ly told

2024’s nov­el drug ap­provals of­fered a wide ar­ray of new can­cer drugs, rare dis­ease treat­ments, a po­ten­tial Alzheimer’s block­buster, and about 10 few­er ap­provals than